A closer look at
vascular instability
Ang-1–Tie2 signalling promotes vascular stability, maintaining homeostasis, whereas Ang-2–Tie2 signalling drives vascular instability, characterised by vascular leakage, inflammation, and neovascularisation.1,2

Mechanisms of disease
DME and nAMD are multifactorial diseases involving numerous signalling pathways that contribute to vascular instability.2 Watch the videos below to discover how Ang-2 and VEGF work together to drive these retinal and choroidal vascular diseases.
Vascular instability
Under conditions of cellular stress (i.e. in diseases such as DME, nAMD, and RVO), an angiogenic switch leads to elevated levels of Ang-2 and VEGF, potentiating angiogenic and inflammatory signals.1
Use the switch to view different conditions
Vascular leakage & neovascularisation
Inflammation

Vascular leakage and neovascularisation1-5
Elevated Ang-2 levels inhibit Tie2, which:
- Primes blood vessels for angiogenesis (pericyte dropout and apoptosis)
- Reduces integrity of endothelial cell junctions, which contributes to vascular leakage
- Amplifies the effects of VEGF on blood vessels
Elevated VEGF levels:
- Promote neovascularisation
- Lead to further vascular leakage

Inflammation1-5
Inhibition of Tie2 by Ang-2 also modulates immune signalling, leading to:
- Leukocyte adhesion to the vessel walls and transmigration into the surrounding tissues
- Release of pro-inflammatory and pro-angiogenic cytokines
- Sensitisation of blood vessels to the effects of cytokines and amplification of those effects
Ang-1–Tie2 signalling
Select a downstream pathway to learn more
Ang-2–Tie2 signalling
Select a downstream pathway to learn more
Context-dependent effects
of Ang-2 signalling
The effects of Ang-2 signalling on endothelial cells are context-dependent and mediated by
several factors, including expression of receptors and modulators and levels of ligands.1,2,8–13
ABIN2, A20-binding inhibitor of NF-κB activation-2; Ang, angiopoietin; DME, diabetic macular edema; eNOS, endothelial nitric oxide synthase; FAK, focal adhesion kinase; FOXO1, forkhead box O1; ICAM1, intercellular adhesion molecule 1; nAMD, neovascular age-related macular degeneration; NF-κB, nuclear factor κB; RVO, retinal vein occlusion; Tie, tyrosine kinase with immunoglobulin-like domains; TNF-α, tumour necrosis factor alpha; VCAM1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VE-PTP, vascular endothelial protein tyrosine phosphate.
References
- Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635–61
- Joussen AM, et al. Eye. 2021;35:1305–16
- Klaassen I, et al. Prog Retin Eye Res. 2013;34:19–48
- Bolinger MT, et al. Int J Mol Sci. 2016;17:1498
- Fiedler U, Augustin HG. Trends Immunol. 2006;27:552–8
- Augustin HG, et al. Nat Rev Mol Cell Biol. 2009;10:165–77
- Akwii RG, et al. Cell. 2019;8:E471
- Lobov IB, et al. Proc Natl Acad Sci U S A. 2002;99:11205–10
- Felcht M, et al. J Clin Invest. 2012;122:1991–2005
- Thomas M, et al. J Biol Chem. 2010;285:23842–9
- Korhonen EA, et al. J Clin Invest. 2016;126:3495–510
- Kim M, et al. J Clin Invest. 2016;126:3511–25
- Souma T, et al. Proc Natl Acad Sci U S A. 2018;115:1298–303